Centrally acting Myorelaxant. Indicated for spastic disorders associated with degenerative illnesses and cerebral palsy. Excreted into breast milk in non-significant clinical amount with no harm effects reported among breastfed infants from treated mothers. When administered in pregnancy, symptoms of Abstinence Syndrome may appear, Intrathecal administration shows small serum levels by which it is assumed that the amount present in breast milk must be even lower. Oral administration has been authorized since neonatal age in the UK and one year of life in Spain. Follow-up of milk production is recommended since a theoretically based inhibition of Prolactin may occur. American Academy of Pediatrics: medication usually compatible with breastfeeding.